Picked up some of this one today, under a buck.. trading at a low valuation of about 37 million $$$. When compared to many other others in this arena, it seems very undervalued given the news of late. Has had a nice bounce back up since the selloff in early December, and had my eyes on this one. Latest news ... Veritas subsidiary obtains Health Canada dealer licence 2017-12-27 14:29 MT - News Release Dr. Lui Franciosi reports VERITAS PHARMA SUBSIDIARY RECEIVES HEALTH CANADA DEALER LICENCE Health Canada has issued Veritas Pharma Inc.'s research and development subsidiary, Cannevert Therapeutics Ltd., dealer licence No. 2018/6970 under Health Canada's Section 9.2 of the Narcotic Control Regulations that will allow it to possess, produce, analyze, sale, send, transport, and deliver cannabis, hemp and related products. This is a significant step for Cannevert in that in conjunction with discovering and developing new therapeutic cannabis strains, it will also be a commercial service provider of chemistry and biological testing services for licensed producers under Health Canada guidelines. Veritas's chief executive officer, Dr. Lui Franciosi, stated: "We are excited that Cannevert scientists will now not only be able to obtain a variety of cannabis strains and related products from multiple licensed producers in Canada, but also from around the world with an acquired import permit. They will also be able to produce cannabis liquid extracts and even send them with an export permit to other parts of the world for further laboratory and clinical trial testing." Although Cannevert's primary focus will continue to be the identification of new cannabis strains for the treatment of specific diseases and conditions, in the new year it will seek to expand its analytical chemistry team, purchase additional testing equipment and lease larger laboratory space on the University of British Columbia campus. The aim is to have a full contract service laboratory operating in later half of 2018. Dr. Franciosi goes on to say, "CTL will have an advantage over other analytical testing service providers in that it will also offer in vivo and in vitro assays to licensed cannabis and hemp producers to determine the therapeutic potential of their strains (for example, batch-to-batch) under a contract research agreement." In the near future Cannevert will also explore the feasibility of securing a licence to grow select cannabis strains for research purposes within its laboratories. It is expected to be a more efficient process given that CTL has gone through the dealer licence application process and the legalization of cannabis will occur in July, 2018. As of Jan. 1, 2018, Cannevert will be one of the over 30 laboratories licensed in Canada to conduct activities with cannabis and hemp: Health Canada: Laboratories licensed to conduct activities with cannabis. About Veritas Pharma Inc. Veritas Pharma is an emerging-stage pharmaceutical and IP (intellectual property) development company, which, through its 80-per-cent-owned Cannevert Therapeutics, is advancing the science behind medical cannabis.
This news right on the heels of the Health Canada release. } Veritas completes prestudy visit of Puerto Rico lab 2017-12-29 04:22 MT - News Release Dr. Lui Franciosi reports VERITAS AND CANNEVERT COMPLETE PRESTUDY VISIT OF THE PUERTO RICO CLINICAL TRIAL FACILITY Veritas Pharma Inc. has completed a prestudy visit of the Fundacion de Investigacion (FDI) facilities in San Juan, Puerto Rico. This will be the site where the company's research arm, Cannevert Therapeutics Ltd. (CTL), will be conducting its first human study of CTL-X, a cannabis strain targeting pain management. As mentioned in a previous release Nov. 20, 2017, a letter of intent (LOI) was signed between CTL and FDI to conduct a human study in two stages. The first stage would use an open-label design to look at the feasibility of two doses of CTL-X in five subjects while the second stage would use a randomized, double-blind, crossover design to assess one dose of CTL-X against a placebo control strain in 16 subjects exposed to various modalities of acute pain. Veritas's chief executive officer Lui Franciosi stated: "I recently travelled to Puerto Rico and visited the FDI clinical trial facility. I was very impressed by their phase 1 and phase 2 to 3 clinical trial units. They were fully staffed and had a complete array of standard medical and laboratory equipment along with a functioning pharmacy." Dr. Franciosi went on to say: "Although the island took a big hit by hurricane Maria this September, most of San Juan's major clinical centres such as the FDI suffered little or no damage. These buildings were able to operate immediately on generator power; the week before my visit, FDI had their electrical power fully restored." While in Puerto Rico, Dr. Franciosi also visited the Institute for Medical Cannabis (IMC) Corp. in Ponce as well as other licensed producers to assess the extent to which the hurricane affected them. He is pleased to report that the facilities sustained little or no damage. IMC was still operating on generator power. IMC mentioned to him that October turned out to be its best month of medical cannabis sales since it started. Dr. Franciosi stated, "We are pleased to see that IMC is fully operational and they are still on track to supply current good manufacturing practice (cGMP) medical cannabis for Cannevert's upcoming study at FDI." Veritas Pharma's goal is to have a branded analgesic strain available starting next year in select markets. This strain's dose and method of administration will be standardized to actively compete with over-the-counter analgesics as well as potentially reduce or eliminate opioid use in the acute and chronic pain. With the help of Cannevert scientists, the company aims to continue providing physicians and patients with scientifically tested and clinically proven cannabis therapies. Today's earlier announcement about Health Canada issuing a dealer licence to Cannevert will only accelerate the company's efforts in bringing new therapeutic strains to market in the coming months and years. About Veritas Pharma Inc. Veritas Pharma is an emerging-stage pharmaceutical and IP (intellectual property) development company, which, through its 80-per-cent-owned Cannevert Therapeutics, is advancing the science behind medical cannabis.
Checked into Health Canada site and there are not many companies with the license under Health Canada's Section 9.2 of the Narcotic Control Regulations that will allow it to possess, produce, analyze, sale, send, transport, and deliver cannabis, hemp and related products. This alone should put the value of the company north of 100 million $$$.. currently VRT.c valued at only 34.5 million $$ cad... There are many so -called marijuana / hemp plays that have NO business to speak of, NO license and trade at multiples of VRT 's value. There are over 80 companies in Canada with a licence to cultivate medicinal pot and or hemp and that number is growing , but only about 30 who have a licence to cultivate and sell. The number of companies is even less, that have the licence that allows transport , export and analyzing capabilities.
A little more info on Veritas deal with Cannavert ( the subsidiary that was granted the licence) Veritas has established an exclusive partner alliance and investment in Cannevert Therapeutics, a high-level research & development company, with facilities at the University of British Columbia (UBC). Bringing together a highly accredited team of pharmacologists, anesthetists, and chemists with substantial prior success in both academia and industry, specifically in drug development. This alliance will provide Veritas with the needed technical ability to deliver on its research, development & commercialization goals. On December 18, 2015, Veritas entered into a Share Purchase Agreement with Cannevert Therapeutics Ltd., a group of academics at The University of British Columbia. Under the terms of the agreement, Veritas has contributed $1.5m over the next 18 months through $250K quarterly installments. After this payment, Veritas now owns 80% of Cannevert. The balance of Cannevert will be acquired with Veritas shares based on independent valuation of Cannevert.
News today again, for some reason ANONYMOUS selling hard at the open. Must not like this fellow. Hard to figure the selling with only good news of late. Veritas Pharma appoints O'Connor to advisory board 2018-01-02 05:59 MT - News Release Dr. Lui Franciosi reports DR. BRIAN O'CONNOR JOINS VERITAS PHARMA ADVISORY BOARD Dr. Brian O'Connor, a consultant in respiratory medicine, has joined Veritas Pharma Inc.'s advisory board. He is a clinical expert in the areas of asthma, Chronic Obstructive Pulmonary Disease ("COPD"), allergic disease, and lung cancer; in addition to, being an active clinical researcher committed to investigating new treatment strategies in Airways Disease. Veritas CEO, Dr. Lui Franciosi stated "Dr. O'Connor brings a great reputation of clinical excellence and scholarly research. He will advise us on how to best position the Company's therapeutic cannabis strains in medical practice as well as assist scientists at our research arm, Cannevert Therapeutics Ltd., with their current research projects." Dr. Brian O' Connor MD, FRCP, FRCPI, is a leading consultant in general and respiratory medicine based in London, United Kingdom. Having graduated in Dublin in 1980, where he completed his general medical training, he passed the entrance exam to become fellow of the Royal College of Physicians of Ireland in 1984 before taking up residence in London. There, he completed his specialist training in respiratory medicine at the reputable Royal Brompton Hospital. While in residence, he established a cutting edge clinical research facility for researching new treatments for airway diseases as well as completing an MD thesis that investigated airway inflammation and asthma. Being committed to research as well as education, he was appointed Senior Lecturer at the National Heart and Lung Institute, the same year he became Consultant in Respiratory Medicine at the Royal Brompton Hospital. In 1997 he continued his clinical research at King's College School of Medicine, becoming Consultant Respiratory Physician at King's College Hospital until 2008, when he took up full-time private practice. He launched the London Chest Clinic in 2009, aiming to tailor healthcare management for patients who want to take charge of their own health whether insured or not. He has published over 200 papers in peer-reviewed journals, edited and written chapters for books, as well as participated in scientific meetings on the international stage. He's an active member of the international respiratory community where he frequently attends meetings and conferences. With expertise in all aspects of respiratory medicine, he takes a special interest in the treatment and management of airway diseases, asthma, smoking-related lung disease, lung cancer, lung infections, and many more. Dedicated to his patients, he provides the best possible bespoke care for each individual case. Veritas Pharma aims to profit from Dr. O'Connor's knowledge and expertise along with the help of its Medical Director, Dr. Scott Alexander in providing physicians and patients with the best clinical advice on the use of its scientifically tested and clinically proven cannabis therapies. Last week's announcement about Health Canada issuance of a Dealer Licence to Cannevert will only accelerate the Company's efforts in bringing new therapeutic strains to market in the coming months and years. .p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 13.0px Arial} p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Arial; color: #666666; min-height: 14.0px} p.p3 {margin: 0.0px 0.0px 0.0px 0.0px; font: 13.0px Verdana} p.p4 {margin: 0.0px 0.0px 0.0px 0.0px; font: 13.0px Verdana; min-height: 16.0px} span.s1 {letter-spacing: 0.0px} Veritas Pharma appoints O'Connor to advisory board 2018-01-02 05:59 MT - News Release Dr. Lui Franciosi reports DR. BRIAN O'CONNOR JOINS VERITAS PHARMA ADVISORY BOARD Dr. Brian O'Connor, a consultant in respiratory medicine, has joined Veritas Pharma Inc.'s advisory board. He is a clinical expert in the areas of asthma, Chronic Obstructive Pulmonary Disease ("COPD"), allergic disease, and lung cancer; in addition to, being an active clinical researcher committed to investigating new treatment strategies in Airways Disease. Veritas CEO, Dr. Lui Franciosi stated "Dr. O'Connor brings a great reputation of clinical excellence and scholarly research. He will advise us on how to best position the Company's therapeutic cannabis strains in medical practice as well as assist scientists at our research arm, Cannevert Therapeutics Ltd., with their current research projects." Dr. Brian O' Connor MD, FRCP, FRCPI, is a leading consultant in general and respiratory medicine based in London, United Kingdom. Having graduated in Dublin in 1980, where he completed his general medical training, he passed the entrance exam to become fellow of the Royal College of Physicians of Ireland in 1984 before taking up residence in London. There, he completed his specialist training in respiratory medicine at the reputable Royal Brompton Hospital. While in residence, he established a cutting edge clinical research facility for researching new treatments for airway diseases as well as completing an MD thesis that investigated airway inflammation and asthma. Being committed to research as well as education, he was appointed Senior Lecturer at the National Heart and Lung Institute, the same year he became Consultant in Respiratory Medicine at the Royal Brompton Hospital. In 1997 he continued his clinical research at King's College School of Medicine, becoming Consultant Respiratory Physician at King's College Hospital until 2008, when he took up full-time private practice. He launched the London Chest Clinic in 2009, aiming to tailor healthcare management for patients who want to take charge of their own health whether insured or not. He has published over 200 papers in peer-reviewed journals, edited and written chapters for books, as well as participated in scientific meetings on the international stage. He's an active member of the international respiratory community where he frequently attends meetings and conferences. With expertise in all aspects of respiratory medicine, he takes a special interest in the treatment and management of airway diseases, asthma, smoking-related lung disease, lung cancer, lung infections, and many more. Dedicated to his patients, he provides the best possible bespoke care for each individual case. Veritas Pharma aims to profit from Dr. O'Connor's knowledge and expertise along with the help of its Medical Director, Dr. Scott Alexander in providing physicians and patients with the best clinical advice on the use of its scientifically tested and clinically proven cannabis therapies. Last week's announcement about Health Canada issuance of a Dealer Licence to Cannevert will only accelerate the Company's efforts in bringing new therapeutic strains to market in the coming months and years.
2018-01-03 06:30 MT - News Release NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- NetworkNewsAudio, via NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company that delivers a new generation of social communication solutions for business, today announces the online availability of its interview with Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP), an emerging pharmaceutical and IP development company who, through its 80 percent owned subsidiary Cannevert Therapeutics Ltd., is advancing the science behind medical cannabis. The interview can be heard at https://www.networknewswire.com/networknewsaudio/veritas-pharma-inc-cse-vrt-otc-vrthf-interview/ NNW’s Stuart Smith shares a lively discussion with Veritas Pharma CEO Dr. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry. Veritas Pharma’s focus is on medicinal marijuana and the alternative medical applications and therapies the cannabis plant can provide to patients. “We have the ability to discover drugs and that in itself makes us very distinct, compared to the rest of the landscape,” Franciosi says in praising the scientists, physicians, and other industry specialists on Veritas Pharma’s team. “So, there is a track record of discovery. The actual strains (of cannabis) that we’ve been looking at, the idea is to chemically profile these so that there’s a unique fingerprint.” Once a specific cannabis strain is scientifically identified, the goal is to be able to reproduce that exact strain repeatedly so that doctors and patients can expect the same therapeutic effect over and over again at least 80 percent of the time, Franciosi explains. “That standardization is what a lot of physicians want. We’re trying to guarantee, give some sort of warranty, that there will be a regular effect when you take this medication,” he says, adding the company’s research arm – Cannevert Therapeutics Ltd. – received a provisional patent application from the U.S. Patent and Trademark Office for using specific cannabis strains for neuropathic pain. “Neuropathic pain is a debilitating pain…it’s ongoing,” Franciosi says. “This is one of our first patent applications that we’ve submitted targeting neuropathic pain.” Veritas Pharma already holds a Health Canada exemption to conduct scientific research with cannabis sourced from one or two legal suppliers in the country. Franciosi said the company is getting closer to receiving a dealer production license, which would allow Veritas Pharma to import and export different varieties of cannabis from around the world. Additionally, the company is now able to become a commercial lab that provides chemical and biological tests for cannabis samples in the Canadian marketplace. The company is also seeking a license to grow and sell specifically cultivated strains of marijuana for medicinal purposes. “I think that’s the excitement that’s coming; that we will eventually have branded medicine with the Veritas logo saying it’s been scientifically tested. I think that will be the highlight of 2018,” Franciosi said in conclusion.
Veritas Pharma summarizes 2017 activities 2018-01-04 15:37 MT - News Release Dr. Lui Franciosi reports VERITAS PHARMA PROVIDES YEAR END UPDATE ON COMPANY'S ACTIVITIES TO SHAREHOLDERS Veritas Pharma Inc. has provided an update to its prospective and current Veritas shareholders regarding the company's activities and milestones over 2017, and strategies for growth in the new year. Veritas Pharma has experienced tremendous activity over the past year, and shareholders have responded positively to our continued efforts to build a diversified portfolio of cannabis investments for Veritas Pharma. The Company has successfully raised multiple rounds of capital to support the various projects that we are developing in North America, including those in British Columbia, Puerto Rico and beyond. Veritas CEO Dr. Lui Franciosi stated, "The last year was formative in Veritas development and we look forward to press forward with expansion plans with a larger footprint and exposure in the cannabis industry in both Canada, Germany and United states in 2018. I'd like to take this opportunity to thank all of our shareholders and supporters for helping us reach this next level of our business plan. We look forward to your continued support of Veritas Pharma and Cannevert Therapeutics Ltd." Research Activities In December, Veritas and Cannevert completed a completed a pre-study visit of the Fundacion de Investigacion (FDI) facilities in San Juan, Puerto Rico. This will be the site where the Company's research arm, Cannevert Therapeutics Ltd. will be conducting its first human study of CTL-X, a cannabis strain targeting pain management. In December, Veritas research arm Cannevert Therapeutics Ltd. signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico. IMC will provide Cannevert with specific cannabis strains for upcoming human studies in the US territory. In October, Veritas research arm Cannevert Therapeutics Ltd. has hired Medrio Inc. of San Francisco, CA, to provide a data collection through their revolutionary CloudEDC{A ™} technology platform for upcoming clinical trials of its cannabis strains in pain management. In July, announced that it is proceeding towards clinical trials with research arm Cannevert Therapeutics Ltd., and sent a team overseas to assess more medicinal cannabis licensed producers as well as clinical research organizations to determine their potential as sources of cannabis material and clinical trial sites, respectively. In May, Veritas research arm Cannevert Therapeutics Ltd. is in development of its medicinal cannabis pipeline and expanded to include anti-emesis (anti-nausea/vomiting) therapies. The mission is to identify and develop the most effective proprietary cannabis strains for pain, emesis and PTSD through a scientific approach that allows the Company to provide doctors and patients with comprehensive evidence of efficacy to provide confidence in prescribing and using these proprietary strains. In February, Veritas research arm Cannevert Therapeutics Ltd, provided the Company with its latest research report outlining its progress with cannabis strains. In Cannevert's report, the strength and mix of research expertise and skillsets were highlighted along with the 'lean and mean' approach of being a discovery company. It also discussed the efficiency of identifying and quantifying all cannabinoids from various cannabis strains, the status of intellectual property protection of strains with therapeutic potential, and the plans for upcoming clinical trials in acute and chronic pain. There was also mention of some positive unexpected findings from animal studies, which will be further investigated and protected in due course. Pursuant to this study, initial meetings were made in the Netherlands with respect to the commencement of human trials. Health Canada Dealer License In December, Veritas announced that Health Canada had issued its research and development subsidiary, Cannevert Therapeutics Ltd. a dealer license no. 2018/6970 under Health Canada's Section 9.2 of the Narcotic Control Regulations ("NCR") that will allow them to possess, produce, analyze, sale, send, transport, and deliver cannabis, hemp and related products. Cancer Research Project In November, the Company announced that it has initiated a cancer research project with Dr. Dmitri Petchkovski to assess the effects of several human cancer cell lines against select cannabis strains, along with standard clinical chemotherapeutic drugs for comparison. Veritas' research arm, Cannevert Therapeutics Ltd. is providing Dr. Petchkovski with the required strains and oversee the implementation of this project. Sechelt Organic Marijuana Corp. In November, Veritas entered into a binding Letter of Intent to Secure ACMPR License and Cannabis Growing Facility in Sechelt, BC., with 906474 Alberta Ltd. subject to regulatory authority to acquire 100% ownership of Sechelt Organic Marijuana Corp., free and clear of all liens, charges and encumbrances in exchange for $800,000 payable in shares of Veritas priced at the last trading day immediately preceding the Closing. Veritas is also issuing to 906474 Special Warrant Shares which would entitle 906474 to additional shares of Veritas equal to $800,000 less the current market price of the Veritas Shares times the market price on last trading day immediately following the 4 month holding period. In July, announced that it is preparing to begin construction of a state-of-the-art cannabis growing facility upon receiving Health Canada's license under Access to Cannabis for Medical Purposes Regulations (ACMPR). Veritas Pharma, through its subsidiary Sechelt Organic Marijuana Corp., has initiated the tendering process and is awaiting bids for the construction of its proposed growing facility. Advisory Board Mr. Peter Doig was appointed to the Advisory Board in July. Mr. Doig is a Professional Agrologist with over 18 years of experience in Compost Bioengineering, organic soils and fertilizers, Biochemistry, Microbiology, and Agricultural Production. For the past 12 years Mr. Doig has consulted and worked in professional greenhouses, as well as several Health Canada Licensed Producers, and Applicants. He has overseen and written standards for certified organic greenhouse production of fruits and vegetables as well as the only Canadian Standards that are specific to cannabis cultivation. Peter joins our advisory board as an expert in cultivation and regulatory compliance. Mr. Robert Dawson a "Top 40 Under 40" recipient was appointed to the Advisory Board in November. Mr. Dawson is a performance-driven and innovative executive with over 20 years of global experience in business leadership, strategic marketing, consulting, technology, crowdsourcing, innovation and communications. He is currently President and CEO of Tectonic Strategy Inc., a boutique innovation and business model advisory firm for technology companies. Fundacion de Investigacion (FDI) In November, Veritas' research arm Cannevert Therapeutics signed letter of intent with Fundacion de Investigacion of Puerto Rico to conduct the first human study of CTL-X, its lead cannabis strain targeting pain. The study will be done in two stages to assess the analgesic effects of this lead strain. The first stage will have an open label design to look at the feasibility of two doses of CTL-X in 5 subjects while the second stage will use a randomized, double- blind, crossover design to assess one dose of CTL-X against a placebo control strain in 16 subjects who will be exposed to various modalities of acute pain. Veritas Hires Medical Director Dr. M. Scott Alexander was hired in December as the Company's Medical Director. Dr. Alexander's primary duties will be to advise physicians and regulators on the application of Cannevert's experimental results with specific cannabis strains to their clinical practice and public policy. He will specifically address their current concerns and need for a standardized medical cannabis product that can be dosed and delivered reliably for a consistent therapeutic effect with minimal side effects. Dr. Alexander is committed to following the principles of translational medicine and developing strong partnerships with patient advocacy groups and colleges of family physicians to share his understanding of the potential benefits and risks of medical cannabis. US Patent Application Veritas announced in November that its research arm, Cannevert Therapeutics Ltd., had filed a provisional patent application to US Patent and Trademark Office (the "USPTO") on September 13, 2017 for use of a specific cannabis strain to enhance the actions of opioid analgesics. An acknowledgement letter from the USPTO was received recently which provided a filing number of US 62/558,021 for this application. Cannevert Therapeutics Ltd. In July, Veritas retained RwE Growth Partners, Inc. to evaluate the Company's $1.50 million investment into its 80% owned research arm, Cannevert Therapeutics Ltd. In April, Veritas announced that it had paid the final installment for a total of $1,500,000 for its acquisition of 80% of the issued and outstanding shares in Cannevert Therapeutics Ltd. and the Company will enter into a second amending agreement with respect to the existing share purchase agreement with Cannevert, with an option to purchase the remaining 20%. Cannevert has effectively been acting as the research arm of Veritas, as it currently has an exclusive license agreement to market all proprietary products developed by them. Additionally, all monetary advances made thus far have been used to expand CTL's R&D efforts. With the latest payment, CTL will provide Veritas with a report on its current research program. We anticipate to have it within the next 10 days, at which point the principal results will be announced. AlphaPheno Inc. In March, Veritas entered into an agreement with AlphaPheno Inc. of Washington State, USA, to collaborate in the area of Research and Development "R&D". Alpha holds a Tier 3 Cultivation and Processing license and therefore is permitted to apply for and hold a R&D license. AlphaPheno has an extensive list of cannabis genetics and existing cultivation space; furthermore, AlphaPheno is applying for a Marijuana Research License to leverage the synergy with Veritas. The License provides for the ability to produce, process and possess marijuana; in addition to, being able to test chemical potency, composition levels, conduct clinical investigations of marijuana derived drug products, conduct research on the efficacy and safety of administering marijuana as part of medical treatment, conduct genomic and agricultural research. AlphaPheno's CEO, Kurt Keating, commented, "We are delighted to work with Veritas Pharma. I believe that this collaboration will achieve great things for the cannabis space and will greatly benefit both companies." Veritas announces the issuance of 2,500,000 stock options at $0.80 to directors, management, and consultants of the Company for a term of twelve (12) months.
Nice rebound today so far. up .12 to .95 on about a million traded today at this point. I expect a good move up for the next month or two.
I see that Veritas does not yet have a licence to cultivate and produce medical cannabis and hemp plants as yet. They do have a licence to buy from another licenced cultivation company and produce products for medical sales. Waiting on the cultivation license for Sechelt operations... once they have that we will see the stock price appreciate to market valuation levels that the other canadian producers enjoy. Current market cap for VRT around 35 million $$. .. which means upon receipt of the cultivation licence , VRT will fully integrated from growing the plants , producing products, analyzing cannabis at their licenced lab , to research and clinical trials for strains of medical pot .
More great news for Veritas , and their research arm Cannavert. Veritas says Cannevert enters clinical research deal 2018-01-10 15:10 MT - News Release Dr. Lui Franciosi reports VERITAS' RESEARCH ARM CANNEVERT SIGNS CLINICAL RESEARCH AGREEMENT FOR HUMAN STUDIES TO ASSESS ITS LEAD CANNABIS STRAIN FOR PAIN Veritas Pharma Inc.'s research arm, Cannevert Therapeutics Ltd. (CTL), has signed a clinical research agreement with the FDI Clinical Research (FDI-CR) in San Juan, Puerto Rico, to conduct the first human study of its lead cannabis strain (CTL-X) targeting pain. This announcement follows a previous release (Nov. 20, 2017), in which CTL announced the signing of a letter of intent with FDI-CR to conduct a human study of CTL-X in two stages. The first stage will have an open-label design to look at the feasibility of two doses of CTL-X in five subjects while the second stage will use a randomized, double-blind, crossover design to assess one dose of CTL-X against a placebo control strain in 16 subjects, who will be exposed to various modalities of acute pain. Prof. Michael Walker, president of Cannevert Therapeutics, stated: "Cannevert is pleased to have CTL-X investigated by FDI's clinical researchers, who are experienced in evaluating all types of treatments for pharma and biotech. We want their help in providing physicians and patients with the best possible scientific evidence for CTL-X, as well as our future cannabis therapies." FDI's chief executive officer, Dr. Jose F. Rodriguez Orengo, mentioned: "Cannevert's study sets a precedent for establishing Puerto Rico as a hub for cannabis clinical research. It will be a first for the island in that a locally grown medical cannabis strain will undergo clinical investigation to assess its therapeutic utility, based on preclinical evidence from formal pharmacological and chemical experiments." Veritas Pharma's chief executive officer, Lui Franciosi, indicated: "We are now closer than ever to seeing CTL-X enter in human trials. If FDI's study findings suggest that it can produce analgesia, this strain could be available later this year as an acute pain reliever product in Puerto Rican dispensaries." Veritas intends to have a branded analgesic strain in which its dose and method of administration are standardized to actively compete with over-the-counter pain relievers, as well as to potentially reduce or eliminate opioid use in the acute and chronic pain markets. Puerto Rico is one of the world's best-known pharmaceutical production and development centres with a growing biotech presence. Most of the significant pharmaceutical companies have used this U.S. territory as a manufacturing or outsourcing base due to its established infrastructure, highly skilled labour force, popular tax incentives and immediate access to the U.S. market. Around 60 per cent of Puerto Rico's export value is pharma-related, and over 25 per cent of the country's GDP comes from the pharma industry (Puerto Rico report, 2017). In 2015, the territory legalized the use of medical cannabis to treat at least 14 preapproved conditions, including pain, HIV, cancer, multiple sclerosis, migraines, anxiety and epilepsy. According to the popular on-line magazine PR Health Department's website, it shows that there are nearly 15,000 Puerto Ricans who have paid $25 (U.S.) a year for a permit to use medical cannabis, and there are 32 dispensaries, 11 grow facilities, seven manufacturing centres and two laboratories responsible for analyzing all medical marijuana before it is sold. Veritas announces the issuance of one million stock options at 85 cents to directors, management and consultants of the company for a term of 12 months. About Veritas Pharma Inc. Veritas Pharma is an emerging pharmaceutical and IP (intellectual property) development company, which, through its 80-per-cent-owned subsidiary Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the company's aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL's unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed to market. Veritas's investment in CTL is led by a strong management team, bringing together veteran academic pharmacologists, anesthetists abd chemists. The company's commercial mission is to patent protect IP (cultivars and strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multibillion-dollar global markets.
Read a post on SH about contact to the company regarding future news. SO i decided to also contact IR. Got a very positive response from them. They stated because of the integrity of the medical professionals in Veritas Pahrma it is basically a slamdunk that they will receive the cultivation licence for the Sechelt operation in B.C. They are well financed and no upcoming financings at these levels. When the stock gets above 1 $ there will a expedited forced warrant exercise that was part of the financing agreements in the past. This will add a couple more million $ to coffers, and help them with development of the licensed lab, cultivation facility and the ongoing medical research . So managed to add another small lot at .75 on the late day selloff.
Was down quite big on this one and got stopped out, under .70... i do think the entire sector not a good place to be invested for the next short while.
Saw this update on another board.... Thank you for contacting us. The deal with Sechelt Organic Marijuana is still on. This transaction is dependant on SOM receiving an ACMPR license. The ACMPR application was placed on July 2014 and early in 2017 we were notified that we are in the last review stage. Based on our understanding this application is in good standing and all required work has been completed on our side. At this juncture we cannot proceed any further without being granted the license. However, we are hoping that this can happen soon. Please, do not hesitate to contact me should you have any additional questions. Best Regards, Sam Eskandari | Investor Relations Representative |Veritas Pharma Inc.
Well I've loaded up a modest 30,000 shares at these great prices. Time for lift off. I'm sorry you've lost so much. But I believe now looks like the time to buy. Volume picking up. They'e shaking the tree initiating stop losses to suck up cheap shares.
